Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Dow Global Technologies LLC | 1,309 |
| 2 | Merck Sharp & Dohme LLC | 947 |
| 3 | Novartis AG | 621 |
| 4 | 3M Innovative Properties Co | 477 |
| 5 | 3M Co | 392 |
| 6 | Alza Corp | 323 |
| 7 | Topgolf Callaway Brands Corp | 291 |
| 8 | Bayer Pharma AG | 263 |
| 9 | Vertex Pharmaceuticals Inc | 237 |
| 10 | Merck and Co Inc | 236 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 11,322 |
| 2 | A61K | Medicinal preparations | 10,653 |
| 3 | C07D | Heterocyclic compounds | 5,706 |
| 4 | C08L | Polymer compositions (blends) | 2,960 |
| 5 | Y10T | Cross-reference (technical subjects) | 2,644 |
| 6 | B32B | Layered products | 2,031 |
| 7 | C07K | Peptides | 1,428 |
| 8 | C08J | Working-up of plastics | 1,225 |
| 9 | C12N | Microorganisms, enzymes | 1,220 |
| 10 | C08K | Polymer compositions (additives) | 1,170 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Heart Failure Treatment and Management | 19 |
| 2 | Pulmonary Hypertension Research and Treatments | 8 |
| 3 | Phosphodiesterase function and regulation | 7 |
| 4 | Cardiac electrophysiology and arrhythmias | 5 |
| 5 | Congenital Heart Disease Studies | 4 |
| 6 | Cardiovascular Function and Risk Factors | 2 |
| 7 | Heart Rate Variability and Autonomic Control | 2 |
| 8 | Hemodynamic Monitoring and Therapy | 2 |
| 9 | Ion channel regulation and function | 2 |
| 10 | Mechanical Circulatory Support Devices | 2 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | André Denault | Montreal Heart Institute | 21 |
| 2 | Wilson S. Colucci | Brigham and Women's Hospital | 12 |
| 3 | A. J. Porsius | Utrecht University | 9 |
| 4 | Alexandre Mebazaa | Hôpital Lariboisière | 8 |
| 5 | A. Farah | Sterling Research Group (United States) | 7 |
| 6 | Afif El‐Khuffash | Rotunda Hospital | 7 |
| 7 | Adawia A. Alousi | Sterling Research Group (United States) | 6 |
| 8 | Akihiro Narimatsu | Mitsubishi Group (Japan) | 6 |
| 9 | Annik Fortier | Université de Montréal | 3 |
| 10 | Christopher M. O’Connor | Clinical Research Institute | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure | 1991 | 2236 | Heart Failure Treatment and Management |
| Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure<SUBTITLE>A Randomized Controlled Trial</SUBTITLE> | 2002 | 1172 | Heart Failure Treatment and Management |
| cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action | 2010 | 1023 | Nitric Oxide and Endothelin Effects |
| Clinical features, diagnosis, and management of enterovirus 71 | 2010 | 833 | Viral Infections and Immunology Research |
| Efficacy and Safety of Milrinone in Preventing Low Cardiac Output Syndrome in Infants and Children After Corrective Surgery for Congenital Heart Disease | 2003 | 767 | Heart Failure Treatment and Management |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular weight of Milrila?
Which organizations hold the most patents related to this compound?
What are the primary research topics associated with this compound?
Who are the most prolific authors publishing on this compound?
What are the highest-impact publications on this compound?